As of today (2024-06-09), Bausch & Lomb's share price is $15.32.
Bausch & Lomb's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.37. Hence, Bausch & Lomb's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Bausch & Lomb's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 6 years, Bausch & Lomb's highest Price-to-Free-Cash-Flow Ratio was 62.62. The lowest was 10.12. And the median was 34.22.
BLCO's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 34.37 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Bausch & Lomb was -219.00% per year.
During the past 6 years, Bausch & Lomb's highest 3-Year average Free Cash Flow per Share Growth Rate was -0.70% per year. The lowest was -34.30% per year. And the median was -17.50% per year.
Bausch & Lomb Price-to-Free-Cash-Flow Historical Data
The historical data trend for Bausch & Lomb's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bausch & Lomb's Price-to-Free-Cash-Flow
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Price-to-Free-Cash-Flow falls into.
Bausch & Lomb Price-to-Free-Cash-Flow Calculation
Bausch & Lomb's Price-to-Free-Cash-Flow ratio for today is calculated as
Bausch & Lomb's Share Price of today is $15.32. Bausch & Lomb's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Bausch & Lomb Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Bausch & Lomb's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Bausch & Lomb (Bausch & Lomb) Business Description
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLCO has been successfully added to your 